Green Cross Holdings Corporation (005257.KS)

KRW 23150.0

(1.09%)

EBITDA Summary of Green Cross Holdings Corporation

  • Green Cross Holdings Corporation's latest annual EBITDA in 2023 was 109.81 Billion KRW , down -36.65% from previous year.
  • Green Cross Holdings Corporation's latest quarterly EBITDA in 2024 Q3 was 39.6 Billion KRW , up 125.0% from previous quarter.
  • Green Cross Holdings Corporation reported an annual EBITDA of 187.04 Billion KRW in 2022, down -25.39% from previous year.
  • Green Cross Holdings Corporation reported an annual EBITDA of 159.01 Billion KRW in 2021, up 174.31% from previous year.
  • Green Cross Holdings Corporation reported a quarterly EBITDA of 4.7 Billion KRW for 2024 Q1, down -55.61% from previous quarter.
  • Green Cross Holdings Corporation reported a quarterly EBITDA of 39.6 Billion KRW for 2024 Q3, up 125.0% from previous quarter.

Annual EBITDA Chart of Green Cross Holdings Corporation (2023 - 2007)

Historical Annual EBITDA of Green Cross Holdings Corporation (2023 - 2007)

Year EBITDA EBITDA Growth
2023 109.81 Billion KRW -36.65%
2022 187.04 Billion KRW -25.39%
2021 159.01 Billion KRW 174.31%
2020 168.79 Billion KRW 6.05%
2019 57.8 Billion KRW -11.1%
2018 97.77 Billion KRW -21.49%
2017 115.05 Billion KRW -1.8%
2016 115.84 Billion KRW -29.27%
2015 120.08 Billion KRW 12.62%
2014 120.26 Billion KRW 54.03%
2013 97.23 Billion KRW 5.02%
2012 90.41 Billion KRW -12.09%
2011 102.49 Billion KRW -36.1%
2010 159.3 Billion KRW 18.19%
2009 130.95 Billion KRW 160.13%
2008 76.37 Billion KRW -18.73%
2007 64.41 Billion KRW 0.0%

Peer EBITDA Comparison of Green Cross Holdings Corporation

Name EBITDA EBITDA Difference
ORIENT BIO Inc. 15.66 Billion KRW -600.899%
Green Cross Holdings Corporation 66.84 Billion KRW -64.285%
Pharmicell Co., Ltd. 8.44 Billion KRW -1201.015%
Green Cross Corporation 109.81 Billion KRW 0.0%
GeneOne Life Science, Inc. -63.69 Billion KRW 272.39%
Celltrion, Inc. 897.26 Billion KRW 87.762%
Samsung Biologics Co.,Ltd. 1603.46 Billion KRW 93.152%
SK bioscience Co.,Ltd. 22.77 Billion KRW -382.111%
SK Biopharmaceuticals Co., Ltd. -22.2 Billion KRW 594.535%
Prestige BioPharma Limited -31.04 Billion KRW 453.684%